Name of journal: *World Journal of Clinical Urology*

ESPS Manuscript NO: 11580

Columns: MINIREVIEW

**Stress urinary incontinence in women and cell therapy: What can we expect from the future?**

Zambon JP *et al.* Stress urinary incontinence in women and cell therapy

Joao Paulo Zambon, Renata S Magalhaes, Fernando G Almeida

**Joao Paulo Zambon, Renata S Magalhaes,** Wake Forest Institute for Regenerative Medicine, North Carolina, NC 27104, United States

**Joao Paulo Zambon, Fernando G Almeida,** Female Urology Department at Universidade Federal de Sao Paulo, 04021-001 Sao Paulo, Brazil

**Correspondence to: Joao Paulo Zambon, MD, PhD,** Wake Forest Institute for Regenerative Medicine, 170 Exeter Court, Winston Salem, North Carolina, NC 27104, United States. fernandourologia@hotmail.com

**Telephone:** +1-336-6924880

**Received:** May 28, 2014 **Revised:** September 28, 2014

**Accepted:** October 14, 2014

**Published online:**

**Abstract**

Stress urinary incontinence (SUI) is a common disorder that affects a large number of women and their quality of life. The aim of SUI therapy is to restore the existing urethral function *via* physical therapy, biofeedback, pelvic floor rehabilitation, pharmacological therapy, bulking agents and surgical approaches. Currently, the gold standard for the management of SUI is the tension-free vaginal sling, which provides structural support to the female urethra. However, even minimally invasive surgical procedure such as “slings” carries risks for the patients, lost efficacy over the time and has long-term complications. For this reason, new therapeutic modalities are needed. Cell therapy has been emerged as an alternative to be used on the treatment of different diseases. The use of stem cells as a therapeutic option for SUI is an attractive alternative because, theoretically, injected cells could restore functional muscle cells and aid in sphincter closure in women with sphincter-associated incontinence. This study aims to review the current literature regarding evidences for using stem cell therapy on stress urinary incontinence in women.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Stem cell; Stress urinary incontinence; Women; Basic science; Animal model

**Core tip:** This is a review of the current literature regarding the use of stem cell for stress urinary incontinence. It has been focused on cell sources, animal model creation and the possibility of translating this therapy for humans.

Zambon JP, Magalhaes RS, Almeida FG. Stress urinary incontinence in women and cell therapy: What can we expect from the future? *World J Clin Urol* 2014; In press

**INTRODUCTION**

Stress urinary incontinence (SUI) is a common disorder that affects a large number of women and their quality of life. According to the National Center for Health Statistics 16% of adult United States women suffer from moderate to severe urinary incontinence, which has a significant socioeconomic impact with an estimated treatment cost of up to $16 billion annually in the United States[1-4].

The pathophysiology of SUI is multifactorial and poorly understood. It appears to be due to the dysfunction of the sphincteric mechanism of the urethra, changes in connective tissues, poor blood perfusion in the periurethral and submucosal areas, and neuronal dysfunction[5,6].

The aim of SUI therapy is to restore the existing urethral function via physical therapy, biofeedback, pelvic floor rehabilitation, pharmacological therapy, bulking agents and surgical approaches. Currently, the gold standard treatment for the management of SUI is the tension free vaginal sling, which provides structural support to the female urethra through a minimally invasive surgical procedure. However, even minimally invasive surgical procedure carries risks for the patients, lost efficacy over the time and has long-term complications such as voiding dysfunction and “de novo urgency”. For this reason, new therapeutic modalities are needed[7-9].

Cell therapy has been emerged as an alternative to be used on the treatment of different diseases. Despite being described for more than 40 years in hematopoietic system regeneration, their therapeutic potential has been started only in 1999, when the cover of Science, one of the most respected scientific journal, announced “Breakthrough of the year: stem cells show their potential”[10].

The use of stem cells as a therapeutic option for SUI is an attractive alternative because, theoretically, injected cells could restore functional muscle cells and improve the urethral sphincter activity in women with sphincter-associated incontinence. Cell types considered for this therapeutic purpose include bone marrow (BMSC), adult mesenchymal stem cells (MSC), human cord blood stem cells (HCBSC), amniotic fluid derived stem cells (HASC), induced pluripotent stem cells (iPS)[11] This study aims to review the current literature regarding evidences for using stem cell therapy on stress urinary incontinence in women.

**STEM CELLS AND ITS POTENTIAL FOR DIFFERENTIATION**

Stem cells are undifferentiated cells that are defined by their abilities of self-renewal and differentiation capacity[12,13].There is a lack of defined morphologic and molecular characteristics of stem cells. Therefore, they are classified according to their potency. The hierarchic order for stem cells ranges from totipotency to pluri and multipotency to unipotency[14]. Totipotent cells are capable of forming cells of the ectoderm, mesoderm, endoderm, and trophoblast. Pluripotent cells can give rise to cells of the three germ layers, but not extra-embryonic tissues. Multipotent cells can be isolated from the developing germ layers or descended adult organs and are capable of self-renewal and differentiate into multiple cell types. Ultimately, the unipotent cells can differentiate into only one cell type[15-18] (Figure 1).

**EXPERIMENTAL ANIMAL MODEL: AN ESSENTIAL STEP TO DEMONSTRATE THE EFFECTIVENESS OF CELL-BASED THERAPY FOR STRESS URINARY INCONTINENCE**

The development of a reliable experimental animal model is the first step to demonstrate the effectiveness of cell-based therapy for stress urinary incontinence. However, once the physiopathology of SUI has not been well established a reliable animal model for urinary incontinence remains a big challenge[4,11].

Mice, rats, rabbits, pigs, and more recently monkeys have been used in experimental studies. There are different ways to induce urinary incontinence in animals such as vaginal balloon dilation, urethrolysis, urethrolysis and cardiotoxin injection, eletrocauterization of pudendal branches, and bilateral pudendal nerve transection. Despite some studies have shown promising outcomes, the main question that should be addressed is: Any of these current methods reproduce the pathophysiology stress urinary incontinence in women[19-25]?

Badra *et al*[4] published the first study performed in monkeys demonstrating a long-term animal model of stable urethral deficiency. They emphasize that nonhuman primates have a natural menarche, a 28-d menstrual cycle, natural menopause as well as age associated health risks that closely mirror those of women.

The objectives of creating a reliable animal model are to avoid methodological bias and outcomes misinterpretation. In the literature, most of the studies, which demonstrate promising outcomes have a short follow up and were performed in small young animals. Therefore, the translation of this therapy for humans needs further and more detailed investigation[9,11].

**STEM CELLS AND STRESS URINARY INCONTINENCE**

There are two different mechanisms of actions for cell therapy. First, the cells can differentiate, integrate into the site of injury and then, replace the damaged tissue. Second, cells can release cytokines, chemokines, and growth factors, which act in paracrine or endocrine manner. Ideally, autologous cells are always recommended to decrease the risk of immune response and rejection[26].

***Embryonic stem cells***

Embryonic stem cells (ESC) are pluripotent cells derived from blastocysts. These cells propagate readily and remain undifferentiated when cultured with leukemia inhibitory factor (LIF). When LIF is withdrawn, ESCs form aggregates called embryoid bodies that generate a variety of specialized cell types. However, the extraction of these cells involves the destruction of embryos, therefore their use is associated with controversial ethical dilemmas. Despite the self-renewing potential and the capability of differentiation into tissues derived from the three germ layers, embryonic stem cells are associated with uncontrolled growth and teratoma formation. For this reason, embryonic stem cells have never been tested for stress urinary incontinence[27].

***Adult stem cells***

The regenerative capacity of a tissue is determined in part by whether it contains endogenous stem cells. These stem cells remain quiescent in the niche for long periods until they are activated by the requirement of new cells to maintain the tissue or because of the tissue damage. Despite the limited potential of differentiation and self-renewal, adult stem cells are an attractive source of cells for urinary sphincter regeneration. Most of the studies regarding cell-based therapy and SUI were performed using adult stem cells derived from adipose tissue, skeletal muscle, bone marrow, human cord blood, and amniotic fluid[27].

**Bone marrow-derived stem cells:** The bone marrow contains two major populations of stem cells: hematopoietic stem cells (HSCs) and mesenchymal stromal cells (MSC), which provide stromal support for HSCs. It has been demonstrated that bone marrow derived stem cells have in vitro myogenic differentiation potential, and when placed in culture they expressed myosin heavy chain and desmin[8,9,12].

There is a lack of studies correlating SUI and BMSC. Kinebuchi *et al*[28] transplanted BMSC into rat’s injured urethral sphincter. After 13 wk, cell-treated rats did not have improvements on leak point pressure whether compared to controls. On the other hand, Kim *et al*[29] demonstrated that the periurethral injection of BMSC increased the leak point pressure and urethral closure pressure at one-month follow up.

The outcomes regarding BMDSC and SUI are controversial. Some studies have shown histological and functional recovery, whereas other studies have shown no improvements. These conflicting results may be related to different methodologies, animal models, route of administration, and amount of injected cells. The current literature does not have strong evidences that support the use of BMSC for SUI.

**Adipose derived stem cells:** The adipose tissue is derived from mesoderm, is easily accessible and overwhelmingly abundant. It has been demonstrated that under specific conditions the adipose tissue has stem cells, which can differentiate into myogenic, adipogenic, osteogenic, chondrogenic, and neurogenic tissue[30].

Shi *et al*[31] injected a tissue engineering bulking agent composed of adipose-derived stem cells (ADSC) and silk fibrin microspheres in 4 different points around the urethra of rats with urinary incontinence. In this study, urinary incontinence was established by bilateral pudendal nerve transection and confirmed by decreasing leak-point pressure (LPP). Injection of silk fibroin microspheres without cells could recover LPP and lumen area at 4 wk but its efficacy disappears at 8 and 12 wk follow up. The injection of microspheres with ADSC brought long-term efficacy at 8 and 12 wk post-injection and improved the urethral sphincter regeneration[31].

Gy *et al*[32] developed a model of postpartum urinary incontinence in rats through the placement of vaginal balloon dilator for four hours followed by bilateral ovariectomy. They labeled isolated ADSC’s from the peri-ovarian fat with thymidine analog 5-ethynyl-2-deoxyuridine (EdU). After four weeks leak-point pressure and bladder capacity were significantly higher in ADSC-treated rats compared to the balloon-injured ovariectomized rats. Histological analysis of ADSCs treated group demonstrated a higher density of peri-urethral blood vessel and the preservation of the urethral fibromuscular structure[32].

Jack *et al*[30] isolated pluripotent adipose derived stem cells from human lipoaspirate. These cells were stained with Vybrant Red and injected around the urethra of athymic rats. Eight weeks later, injected cells remained viable and randomly distributed in the local submucosa and lamina propria[30].

***Muscle derived stem cells***

There are different cell populations that can be isolated form skeletal muscle biopsies. These cells include myoblasts, satellite cells, muscle progenitor cells, and muscle derived stem cells (MDSC). As well as adipose derived stem cells, it has been demonstrated that adult stem cells isolated from skeletal muscle also have multilineage differentiation capacity[33].

Xu *et al*[34] isolated MDSCs from the hind gastrocnemius of 4-wk-old Wistar rats and infected them with lentivirus encoding green fluorescent protein. In this study, urinary incontinence was established by bilateral pudendal nerve transection and confirmed by leak-point pressure (LPP) decrease. MDSCs were injected at proximal urethra and the animals were sacrificed at four weeks. MDSC-treated rats had higher leak-point pressure and sphincter muscle thickness than controls[34].

Williams *et al*[4] developed a model of urinary sphincter deficiency in adult premenopausal female cynomologus monkeys cauterizing and then bilaterally transecting the pudendal nerve. Autologous muscle progenitor cells were injected at four locations (12, 3, 6 and 9 o’clock positions) around the sphincter area. At 12 mo follow up, cell-treated monkeys had an improvement in resting, somatic and adrenergic nerve stimulated maximal urethral closure pressure, and a greater percentage of sphincter area occupied by muscle. The GFP labeled precursors cells were found in the skeletal muscle layer and expressed desmin and connexin-43. According to the authors it seems reasonable to assume that their outcomes have a high translational values[4].

***Cord blood stem cells***

Cord blood is a rich source of stem cells, including hematopoietic and mesenchymal stem cells, which have been used in the treatment of many diseases, including leukemia, lymphoma and anemia[35].

There are few experimental studies that use stem cells derived from cord blood for SUI therapy[35-37]. Lim *et al*[35] reported the short-term effects of human umbilical cord blood mononuclear transplantation in incontinent rats. Urinary incontinence was created through the electro-cauterization of periurethral soft tissue and confirmed by leak point pressure measurement. At four weeks, cell-treated rats had significant higher leak-point pressure than controls; however, the injected cells were not found in the urethral tissue[35].

***Human amniotic fluid stem cells***

Amniotic fluid, due to its contact with the fetus, has been considered an interesting source for undifferentiated or partially differentiated cells. Human amniotic stem cells (HASC) express surface markers and transcription factors distinctive of embryonic stem cells. These include octamer-binding transcription factor 4 (OCT-4) and stage specific embryonic antigen (SSEA-4). HASCs have high replicative self-renewal potential and multilineage differentiation capacity[38-41].

Chun *et al*[42] injected three different lineages of early differentiation human amniotic fluid-derived cell to restore urinary sphincter function in mice with urinary incontinence. In this study, urinary incontinence was created through bilateral pudendal nerve transection and the follow up was two and four weeks. HASC’s were early differentiated into muscle, neuron, and endothelial progenitor cells, and then injected into the urethral sphincter as a single, double, or triple combination. Urodynamic study showed that mice treated with the three cell populations had better outcomes than the other ones. These functional results were confirmed by histological and immunohistochemical analysis, as evidenced by the formation of new striated muscle fibers and neuromuscular junctions at the cell injection site[42].

***Induced pluripotent stem cells***

Induced pluripotent stem cells (iPSC) were first described by Takahashi and Yamanaka in 2006 when they reprogrammed human fibroblasts to become pluripotent stem cells by the addition of four different genes: Oct3/4, Sox2, c-Myc, and Klf4[43]. Despite being a good source of cells, not all adult stem cells can be reprogrammed using the same method, which means that each cell type may have critical factors. Unlike embryonic stem cells, iPS cells have no ethical issues and no immune rejection. On the other hand, these cells are reprogrammed through the addition of oncogenes, which increase the risk of uncontrolled growth[44]. These cells have never been tested to treat stress urinary incontinence.

**REGENERATIVE MEDICINE OF THE CONNECTIVE TISSUES – PELVIC PROLAPSE AND LIGAMENT REINFORCEMENT**

The current surgical approaches for pelvic organ prolapse treatment are associated with high rates of long-term complications such as erosions, infections, pain, and vagina shrinkage. There is a lack of studies in the literature with regards to cell-therapy and pelvic organ prolapse[45].

Boennelycke *et al*[46] used fresh muscle fiber fragments seeded on synthetic biodegradable methoxy polyethylene glycol-polylactide-co-glycolic acid (MPEG-PLGA) scaffolds implanted subcutaneously on the abdomen of rats. After 8 wk, new striated muscle was created and the scaffolds had disappeared[46]. Petros *et al*[47] implanted mersilene tapes between rectus abdominis and midurerhra in 13 canines for periods of 6-12 wk. They observed a linear deposition of collagen around all implanted tapes and some interstitial macrophages. In this study, the main goal was to reinforce damaged pubourethral ligaments using an autogenic collagenous ligament[47].

Regarding prolapse and regenerative medicine approaches, the current literature does not have sufficient data to support cell-based therapy. Further studies using a reliable animal model, different cell sources and scaffolds should be addressed before clinical use.

**STEM CELL THERAPY AND STRESS URINARY INCONTINENCE – CLINICAL OUTCOMES**

The translation of basic science to humans is the main goal of scientists and researchers. When a new therapy reaches acceptable outcomes in animal models and has the potential to be applied in humans, some issues should be considered before moving forward. Despite expectations inherent to new breakthroughs, a carefully analysis of pros and cons regarding the procedure should be considered to avoid potential avoidable mistakes.

Aref-Adib *et al*[11] published a systematic review addressing the use of stem cell therapy for stress urinary incontinence in humans. They assessed different outcomes such as adverse effects, incontinence, quality of life, urodynamic, transurethral ultrasound and urethral EMG. Out of 89 studies, only eight met the inclusion criteria, which was a quality score tool designed for use in systematic reviews. According to the authors, the outcomes from the studies published to date are promising. Stem cell therapy may improve patients` quality of life as well as objective measures of urinary incontinence. Furthermore, the procedure is safe with minimal adverse effects. However, despite promising results, there is no long-term follow up data and many patients lost to follow up without any explanation and withdrew from the studies[11].

Shrivan *et al*[48] described the safety assessment of urethra injections of autologous nucleated cells (TNCs) harvested from peripheral blood along with platelets in 9 women with stress urinary incontinence. At 6 mo follow up all the patients considered themselves completely cures with 8 women completely continent and one marked improvement. The idea is that peripheral blood has multipotential cell, which can improve the tissue regeneration[48].

**FUTURE PERSPECTIVES AND DIRECTIONS**

The stress urinary incontinence is a benign condition that has other effective, simple, cheap and safe treatment alternatives. I believe that stem cell therapy may be an alternative to treat those patients who has urethral sphincter deficiency and did not respond to well-established procedures. Historically, any new therapeutic modality has an initial enthusiasm; however, as well demonstrated in this paper, there are still few evidences, which support cell-based therapy for SUI. The enthusiasm surrounding the new therapeutic possibility should be replaced by moderation, reflection, and careful analysis of the available data associated with consistent experimental studies. The indiscriminate use without sufficient basic evidence could lead to discredit and retrocession.

**REFERENCES**

1 **Nygaard I**, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, Spino C, Whitehead WE, Wu J, Brody DJ. Prevalence of symptomatic pelvic floor disorders in US women. *JAMA* 2008; **300**: 1311-1316 [PMID: 18799443 DOI: 10.1001/jama.300.11.1311]

2 **Wagner TH**, Hu TW. Economic costs of urinary incontinence in 1995. *Urology* 1998; **51**: 355-361 [PMID: 9510336 DOI: 10.1016/S0090-4295(97)00623-7]

3 **Hu TW**. The economic impact of urinary incontinence. *Clin Geriatr Med* 1986; **2**: 673-687 [PMID: 3536057]

4 **Badra S**, Andersson KE, Dean A, Mourad S, Williams JK. Long-term structural and functional effects of autologous muscle precursor cell therapy in a nonhuman primate model of urinary sphincter deficiency. *J Urol* 2013; **190**: 1938-1945 [PMID: 23618586 DOI: 10.1016/j.juro.2013.04.052]

5 **Rodríguez LV**, Chen S, Jack GS, de Almeida F, Lee KW, Zhang R. New objective measures to quantify stress urinary incontinence in a novel durable animal model of intrinsic sphincter deficiency. *Am J Physiol Regul Integr Comp Physiol* 2005; **288**: R1332-R1338 [PMID: 15650117 DOI: 10.1152/ajpregu.00760.2004]

6 **Fong ED**, Nitti VW. Review article: Mid-urethral synthetic slings for female stress urinary incontinence. *BJU Int* 2010; **106**: 596-608 [PMID: 21050350 DOI: 10.1111/j.1464-410X.2010.09544.x]

7 **Ulmsten U**, Petros P. Intravaginal slingplasty (IVS): an ambulatory surgical procedure for treatment of female urinary incontinence. *Scand J Urol Nephrol* 1995; **29**: 75-82 [PMID: 7618052 DOI: 10.3109/00365599509180543]

8 **Brubaker L**, Norton PA, Albo ME, Chai TC, Dandreo KJ, Lloyd KL, Lowder JL, Sirls LT, Lemack GE, Arisco AM, Xu Y, Kusek JW. Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study. *Am J Obstet Gynecol* 2011; **205**: 498.e1-498.e6 [PMID: 21925636]

9 **Ho CP**, Bhatia NN. Development of stem cell therapy for stress urinary incontinence. *Curr Opin Obstet Gynecol* 2012; **24**: 311-317 [PMID: 22954763]

10 **Vogel G**. Breakthrough of the year. Capturing the promise of youth. *Science* 1999; **286**: 2238-2239 [PMID: 10636772 DOI: 10.1126/science.286.5448.2238]

11 **Aref-Adib M**, Lamb BW, Lee HB, Akinnawo E, Raza MM, Hughes A, Mehta VS, Odonde RI, Yoong W. Stem cell therapy for stress urinary incontinence: a systematic review in human subjects. *Arch Gynecol Obstet* 2013; **288**: 1213-1221 [PMID: 24077813 DOI: 10.1007/s00404-013-3028-0]

12 **Becker C**, Jakse G. Stem cells for regeneration of urological structures. *Eur Urol* 2007; **51**: 1217-1228 [PMID: 17254699 DOI: 10.1016/j.eururo.2007.01.029]

13 **Watt FM**, Hogan BL. Out of Eden: stem cells and their niches. *Science* 2000; **287**: 1427-1430 [PMID: 10688781 DOI: 10.1126/science.287.5457.1427]

14 **Blau HM**, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function? *Cell* 2001; **105**: 829-841 [PMID: 11439179 DOI: 10.1016/S0092-8674(01)00409-3]

15 **Keller G**. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. *Genes Dev* 2005; **19**: 1129-1155 [PMID: 15905405 DOI: 10.1101/gad.1303605]

16 **Evans MJ**, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. *Nature* 1981; **292**: 154-156 [PMID: 7242681 DOI: 10.1038/292154a0]

17 **Conrad C**, Huss R. Adult stem cell lines in regenerative medicine and reconstructive surgery. *J Surg Res* 2005; **124**: 201-208 [PMID: 15820249 DOI: 10.1016/j.jss.2004.09.015]

18 **Reyes M**, Verfaillie CM. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. *Ann N Y Acad Sci* 2001; **938**: 231-233; discussion 231-233 [PMID: 11458512 DOI: 10.1111/j.1749-6632.2001.tb03593.x]

19 **Dissaranan C**, Cruz MA, Couri BM, Goldman HB, Damaser MS. Stem cell therapy for incontinence: where are we now? What is the realistic potential? *Curr Urol Rep* 2011; **12**: 336-344 [PMID: 21842258 DOI: 10.1007/s11934-011-0210-4]

20 **Gräs S**, Lose G. The clinical relevance of cell-based therapy for the treatment of stress urinary incontinence. *Acta Obstet Gynecol Scand* 2011; **90**: 815-824 [PMID: 21564032 DOI: 10.1111/j.1600-0412.2011.01184.x]

21 **Staack A**, Rodríguez LV. Stem cells for the treatment of urinary incontinence. *Curr Urol Rep* 2011; **12**: 41-46 [PMID: 21113694 DOI: 10.1007/s11934-010-0155-z]

22 **Goldman HB**, Sievert KD, Damaser MS. Will we ever use stem cells for the treatment of SUI? ICI-RS 2011. *Neurourol Urodyn* 2012; **31**: 386-389 [PMID: 22431263 DOI: 10.1002/nau.22217]

23 **Lin CS**, Lue TF. Stem cell therapy for stress urinary incontinence: a critical review. *Stem Cells Dev* 2012; **21**: 834-843 [PMID: 22121849 DOI: 10.1089/scd.2011.0621]

24 **Wang HJ**, Chuang YC, Chancellor MB. Development of cellular therapy for the treatment of stress urinary incontinence. *Int Urogynecol J* 2011; **22**: 1075-1083 [PMID: 21505907 DOI: 10.1007/s00192-011-1432-1]

25 **Nikolavasky D**, Stangel-Wójcikiewicz K, Stec M, Chancellor MB. Stem cell therapy: a future treatment of stress urinary incontinence. *Semin Reprod Med* 2011; **29**: 61-70 [PMID: 21207335 DOI: 10.1055/s-0030-1268705]

26 **Loewendorf A**, Csete M. Concise review: immunologic lessons from solid organ transplantation for stem cell-based therapies. *Stem Cells Transl Med* 2013; **2**: 136-142 [PMID: 23349327 DOI: 10.5966/sctm.2012-0125]

27 **Kolaja K**. Stem cells and stem cell-derived tissues and their use in safety assessment. *J Biol Chem* 2014; **289**: 4555-4561 [PMID: 24362027 DOI: 10.1074/jbc.R113.481028]

28 **Kinebuchi Y**, Aizawa N, Imamura T, Ishizuka O, Igawa Y, Nishizawa O. Autologous bone-marrow-derived mesenchymal stem cell transplantation into injured rat urethral sphincter. *Int J Urol* 2010; **17**: 359-368 [PMID: 20202003 DOI: 10.1111/j.1442-2042.2010.02471.x]

29 **Kim SO**, Na HS, Kwon D, Joo SY, Kim HS, Ahn Y. Bone-marrow-derived mesenchymal stem cell transplantation enhances closing pressure and leak point pressure in a female urinary incontinence rat model. *Urol Int* 2011; **86**: 110-116 [PMID: 20689260 DOI: 10.1159/000317322]

30 **Jack GS**, Almeida FG, Zhang R, Alfonso ZC, Zuk PA, Rodríguez LV. Processed lipoaspirate cells for tissue engineering of the lower urinary tract: implications for the treatment of stress urinary incontinence and bladder reconstruction. *J Urol* 2005; **174**: 2041-2045 [PMID: 16217390 DOI: 10.1097/01.ju.0000176489.96993.84]

31 **Shi LB**, Cai HX, Chen LK, Wu Y, Zhu SA, Gong XN, Xia YX, Ouyang HW, Zou XH. Tissue engineered bulking agent with adipose-derived stem cells and silk fibroin microspheres for the treatment of intrinsic urethral sphincter deficiency. *Biomaterials* 2014; **35**: 1519-1530 [PMID: 24275524 DOI: 10.1016/j.biomaterials.2013.11.025]

32 **Li GY**, Zhou F, Gong YQ, Cui WS, Yuan YM, Song WD, Xin H, Liu T, Li WR, Gao ZZ, Liu J, Guo YL, Xin ZC. Activation of VEGF and ERK1/2 and improvement of urethral function by adipose-derived stem cells in a rat stress urinary incontinence model. *Urology* 2012; **80**: 953.e1-953.e8 [PMID: 22950999]

33 **Kwon D**, Kim Y, Pruchnic R, Jankowski R, Usiene I, de Miguel F, Huard J, Chancellor MB. Periurethral cellular injection: comparison of muscle-derived progenitor cells and fibroblasts with regard to efficacy and tissue contractility in an animal model of stress urinary incontinence. *Urology* 2006; **68**: 449-454 [PMID: 16904482 DOI: 10.1016/j.urology.2006.03.040]

34 **Xu Y**, Song YF, Lin ZX. Transplantation of muscle-derived stem cells plus biodegradable fibrin glue restores the urethral sphincter in a pudendal nerve-transected rat model. *Braz J Med Biol Res* 2010; **43**: 1076-1083 [PMID: 21088804 DOI: 10.1590/S0100-879X2010007500112]

35 **Lim JJ**, Jang JB, Kim JY, Moon SH, Lee CN, Lee KJ. Human umbilical cord blood mononuclear cell transplantation in rats with intrinsic sphincter deficiency. *J Korean Med Sci* 2010; **25**: 663-670 [PMID: 20436699 DOI: 10.3346/jkms.2010.25.5.663]

36 **Kong KY**, Ren J, Kraus M, Finklestein SP, Brown RH. Human umbilical cord blood cells differentiate into muscle in sjl muscular dystrophy mice. *Stem Cells* 2004; **22**: 981-993 [PMID: 15536189 DOI: 10.1634/stemcells.22-6-981]

37 **Feki A**, Faltin DL, Lei T, Dubuisson JB, Jacob S, Irion O. Sphincter incontinence: is regenerative medicine the best alternative to restore urinary or anal sphincter function? *Int J Biochem Cell Biol* 2007; **39**: 678-684 [PMID: 17208507 DOI: 10.1016/j.biocel.2006.11.001]

38 **De Coppi P**, Bartsch G, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, Furth ME, Soker S, Atala A. Isolation of amniotic stem cell lines with potential for therapy. *Nat Biotechnol* 2007; **25**: 100-106 [PMID: 17206138 DOI: 10.1038/nbt1274]

39 **Perin L**, Giuliani S, Jin D, Sedrakyan S, Carraro G, Habibian R, Warburton D, Atala A, De Filippo RE. Renal differentiation of amniotic fluid stem cells. *Cell Prolif* 2007; **40**: 936-948 [PMID: 18021180 DOI: 10.1111/j.1365-2184.2007.00478.x]

40 **Perin L**, Sedrakyan S, Giuliani S, Da Sacco S, Carraro G, Shiri L, Lemley KV, Rosol M, Wu S, Atala A, Warburton D, De Filippo RE. Protective effect of human amniotic fluid stem cells in an immunodeficient mouse model of acute tubular necrosis. *PLoS One* 2010; **5**: e9357 [PMID: 20195358 DOI: 10.1371/journal.pone.0009357]

41 **Da Sacco S**, De Filippo RE, Perin L. Amniotic fluid as a source of pluripotent and multipotent stem cells for organ regeneration. *Curr Opin Organ Transplant* 2011; **16**: 101-105 [PMID: 21157345 DOI: 10.1097/MOT.0b013e3283424f6e]

42 **Chun SY**, Kwon JB, Chae SY, Lee JK, Bae JS, Kim BS, Kim HT, Yoo ES, Lim JO, Yoo JJ, Kim WJ, Kim BW, Kwon TG. Combined injection of three different lineages of early-differentiating human amniotic fluid-derived cells restores urethral sphincter function in urinary incontinence. *BJU Int* 2014; Epub ahead of print [PMID: 24841807 DOI: 10.1111/bju.12815]

43 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]

44 **Theunissen TW**, Jaenisch R. Molecular control of induced pluripotency. *Cell Stem Cell* 2014; **14**: 720-734 [PMID: 24905163 DOI: 10.1016/j.stem.2014.05.002]

45 **Abed H**, Rahn DD, Lowenstein L, Balk EM, Clemons JL, Rogers RG. Incidence and management of graft erosion, wound granulation, and dyspareunia following vaginal prolapse repair with graft materials: a systematic review. *Int Urogynecol J* 2011; **22**: 789-798 [PMID: 21424785 DOI: 10.1007/s00192-011-1384-5]

46 **Boennelycke M**, Gras S, Lose G. Tissue engineering as a potential alternative or adjunct to surgical reconstruction in treating pelvic organ prolapse. *Int Urogynecol J* 2013; **24**: 741-747 [PMID: 22940843 DOI: 10.1007/s00192-012-2022-6]

47 **Petros PE**. Tissue engineering: creation of an autogenic collagenous neoligament to cure urinary stress incontinence. *Int Urogynecol J* 2013; **24**: 1769-1770 [PMID: 23942976 DOI: 10.1007/s00192-013-2192-x]

48 **Shirvan MK**, Alamdari DH, Mahboub MD, Ghanadi A, Rahimi HR, Seifalian AM. A novel cell therapy for stress urinary incontinence, short-term outcome. *Neurourol Urodyn* 2013; **32**: 377-382 [PMID: 22972395 DOI: 10.1002/nau.22301]

**P-Reviewer:** De Petro G, Niyibizi C, Sacco E **S-Editor:** Ji FF **L-Editor: E-Editor:**

****

**Figure 1 Stem cells and its potential for differentiation.** Adapted from Ref. [12]. ESC: Embryonic stem cells; EGC: Embryonic germ cells; SC: Stem cells; HSC: Hematopoietic stem cells; MSC: Mesenchymal stem cells.